Virtual Public Webinar Series:

Advancing Pathways for the Development of Innovative Therapies for Children with Inflammatory Bowel Disease

Inflammatory bowel disease (IBD), once considered rare in children, is now common enough that most pediatricians and clinicians will encounter children with some type of IBD. Addressing the needs of children with IBD related to drug development of new therapies has emerged as a challenging issue. The goal of this Forum is to identify how these challenges can be met.

Register to join I-ACT for Children to discuss:

  • Developing of solutions to move our industry forward and advance pathways for regulatory approval and labeling of IBD therapies for use in children
  • Bringing together all stakeholders to gain perspective and solutions, including patients and families, clinicians, sponsors and regulators
  • Identifying gaps in knowledge that impact the development process and recommend actionable items to address these gaps
  • Constructing a road map that can be used by investigators, funding agencies and sponsors to support further advancement of pediatric IBD therapeutics development

Register for the Virtual Public Webinar Series hosted by I-ACT for Children

Nov. 9, 9:00-13:00 ET, (15:00 to 19:00 CET)
Perspectives: Patient, Family and Healthcare Providers

Nov. 10, 9:00-13:00 ET, (15:00 to 19:00 CET)
Data Extrapolation

Nov. 17, 9:00-13:00 ET, (15:00 to 19:00 CET)
Real-World Data (RWD)/Real-World Evidence (RWE), Biomarkers & Endpoints

Jan. 2022 (date to be determined)
Clinical Trial Designs and relevant discussion points from the first three webinars

This Forum has been supported in part by a grant from the US Food and Drug Administration (award #5Y18FD006297), in addition to educational grants received from Eli Lilly and Company, Janssen Research & Development LLC, and the Pharmaceutical Research and Manufacturers of America.

PhRMA Logo

©2021 I-ACT for Children | Privacy Statement | Terms of Use